Pulmonary Arterial Hypertension (PAH) Market in China 2021

USD 450

Product Type

Industry Statistics

Release Date

15 March 2021

Region

Asia Pacific

Release Year

2021

Table of Contents
    Add a header to begin generating the table of contents

    Description

    The pulmonary arterial hypertension (PAH) market in China in terms of revenue is set to grow by US$ 787 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 49.6% during the forecast period, according to data and analytics company StrategyHelix.

    The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for pulmonary arterial hypertension (PAH). The China pulmonary arterial hypertension (PAH) market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

    The report has profiled some of the key players of the market such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.

    The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pulmonary arterial hypertension (PAH) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


    Report Scope

    Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
    Years Considered: this report covers the period 2017 to 2027


    Key Benefits for Stakeholders

    Get a comprehensive picture of the China pulmonary arterial hypertension (PAH) market
    Pinpoint growth sectors and trends for investment
    Understand what the future of the pulmonary arterial hypertension (PAH) market in China looks like
    Identify the competitive landscape and window of opportunity


    Table of Contents

    1. Market Definition
    2. Research Methodology
    3. Market Data & Outlook
    3.1 Market Value
    3.2 Market Value Forecast
    4. Pulmonary Arterial Hypertension (PAH) Market by Region
    4.1 Central South China
    4.2 East China
    4.3 North China
    4.4 Northeast China
    4.5 Northwest China
    4.6 Southwest China
    5. Company Profiles
    5.1 Actelion Pharmaceuticals Ltd.
    5.2 Bayer AG
    5.3 Beijing Tide Pharmaceutical Co., Ltd.
    5.4 GlaxoSmithKline plc
    5.5 United Therapeutics Corporation
    6. Appendix
    6.1 About StrategyHelix
    6.2 Disclaimer


    StrategyHelix Black LOGO

    REQUEST SAMPLE

    Please fill out our form and we will get back to you.

    Pulmonary Arterial Hypertension (PAH) Market in China 2021

    StrategyHelix Black LOGO

    CUSTOM RESEARCH

    Custom projects can be researched to match your unique needs.

    Pulmonary Arterial Hypertension (PAH) Market in China 2021

    login